التفاصيل البيبلوغرافية
| العنوان: |
New Approaches in Early-Stage NSCL Management: Potential Use of PARP Inhibitors and Immunotherapy Combination |
| المؤلفون: |
Marta Pina Fernandes, Cristina Oliveira, Hugo Sousa, Júlio Oliveira |
| المصدر: |
International Journal of Molecular Sciences; Volume 24; Issue 4; Pages: 4044 |
| بيانات النشر: |
Multidisciplinary Digital Publishing Institute |
| سنة النشر: |
2023 |
| المجموعة: |
MDPI Open Access Publishing |
| مصطلحات موضوعية: |
non-small cell lung cancer, EARLY-stage NSCLC, PARP inhibitors, immunotherapy, combination therapy, neoadjuvant setting |
| جغرافية الموضوع: |
agris |
| الوصف: |
Lung cancer is the second most common cancer in the world, being the first cause of cancer-related mortality. Surgery remains the only potentially curative treatment for Non-Small Cell Lung Cancer (NSCLC), but the recurrence risk remains high (30–55%) and Overall Survival (OS) is still lower than desirable (63% at 5 years), even with adjuvant treatment. Neoadjuvant treatment can be helpful and new therapies and pharmacologic associations are being studied. Immune Checkpoint Inhibitors (ICI) and PARP inhibitors (PARPi) are two pharmacological classes already in use to treat several cancers. Some pre-clinical studies have shown that its association can be synergic and this is being studied in different settings. Here, we review the PARPi and ICI strategies in cancer management and the information will be used to develop a clinical trial to evaluate the potential of PARPi association with ICI in early-stage neoadjuvant setting NSCLC. |
| نوع الوثيقة: |
text |
| وصف الملف: |
application/pdf |
| اللغة: |
English |
| العلاقة: |
Molecular Oncology; https://dx.doi.org/10.3390/ijms24044044Test |
| DOI: |
10.3390/ijms24044044 |
| الإتاحة: |
https://doi.org/10.3390/ijms24044044Test |
| حقوق: |
https://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: |
edsbas.CBE0A13D |
| قاعدة البيانات: |
BASE |
